Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Appointed director
CC transcript
Inv. presentation
Acq. announced
NeurogesX Inc (NGSX) Create: Alert

All | News | Filings
Date FiledTypeDescription
07/11/2013 8-K Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Completion of Acquisition or Disp...
06/24/2013 8-K Quarterly results
04/17/2013 8-K Acquisition/merger/asset purchase announced
03/27/2013 8-K SEC Filing in the EDGAR database
03/11/2013 8-K Entry into a Material Definitive Agreement, Other Events
03/05/2013 8-K Cost Associated with Exit or Disposal Activities, Other Events
01/08/2013 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
11/30/2012 8-K Cost Associated with Exit or Disposal Activities, Other Events
11/14/2012 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
09/14/2012 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
08/24/2012 8-K Entry into a Material Definitive Agreement, Departure of Directors or Certain Officers; Election of Directors; Appointment of...
08/07/2012 8-K Other Events, Financial Statements and Exhibits
Docs: "NeurogesX Provides Regulatory Update For NGX-1998 Clinical Program End-of Phase 2 FDA Guidance Supports Plan To Enter Phase 3 Development Later This Year San Mateo, Calif., - NeurogesX, Inc. , a specialty pharmaceutical company focused on developing and commercializing a portfolio of novel non-opioid, pain management therapies, today provided an update on its regulatory process for NGX-1998, the Company's next generation liquid formulation of prescription-strength capsaicin. NeurogesX recently received End-of-Phase 2 guidance from the U.S. Food and Drug Administration regarding its previously announced plans for the Phase 3 clinical development of NGX-1998 as a treatment for neuropathic pain conditions, including key elements of its overall development plan related to manufacturing, applic..."
08/03/2012 8-K Quarterly results
Docs: "NeurogesX Reports Second Quarter 2012 Results Q2 2012 and Recent Highlights:"
08/02/2012 8-K Other Events, Financial Statements and Exhibits
Docs: "NeurogesX Receives Additional Notice of Allowance Covering NGX-1998 in U.S. San Mateo, Calif., - NeurogesX, Inc. , a specialty pharmaceutical company focused on developing and commercializing a portfolio of novel non-opioid, pain management therapies, today announced it has received an additional notice of allowance from the United States Patent and Trademark Office related to the company's family of patents for NGX-1998, the Company's next generation liquid formulation of prescription-strength capsaicin. The allowed patent application expands on the Company's patent entitled, “Methods and compositions for administration of TRPV1 agonists.” The claims in the allowed application relate to methods of treating capsaicin-responsive conditions with a liquid formulation containing between 10% an..."
06/29/2012 8-K Form 8-K - Current report
06/11/2012 8-K Submission of Matters to a Vote of Security Holders
05/03/2012 8-K Quarterly results
Docs: "NeurogesX Reports First Quarter 2012 Results Q1 2012 and Recent Highlights: • Engaged JSB-Partners, a global life sciences advisor, to assist the Company in executing its business development objectives for NGX-1998 and Qutenza ® • FDA accepted the Company's request for an End-of-Phase 2 meeting to discuss plans for Phase 3 development of the Company's next generation product candidate NGX-1998 • Realigned resources to focus on next generation, prescription-strength capsaicin product candidate NGX-1998; eliminated direct promotion of Qutenza"
04/27/2012 8-K Form 8-K - Current report
04/19/2012 8-K Other Events, Financial Statements and Exhibits
Docs: "NeurogesX Engages JSB-Partners to Execute Business Development Strategy"
04/09/2012 8-K Entry into a Material Definitive Agreement
03/13/2012 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
03/08/2012 8-K Quarterly results
Docs: "NeurogesX Reports Fourth Quarter and Year-End 2011 Results Implements Restructuring to Focus on NGX-1998 Development Q4 2011 and Recent Highlights:"
02/06/2012 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits
Docs: "Form of Registration Rights Agreement",
"Form of Securities Purchase Agreement"
02/01/2012 8-K Other Events, Financial Statements and Exhibits
Docs: "NeurogesX, Inc. Announces $3.0 Million Private Placement"
01/30/2012 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
01/03/2012 8-K Form 8-K - Current report
11/14/2011 8-K Form 8-K - Current report
11/08/2011 8-K Form 8-K - Current report
10/31/2011 8-K Form 8-K - Current report
10/31/2011 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "NeurogesX Appoints Dr. Stephen J. Peroutka as Executive Vice President and Chief Medical Officer"
09/27/2011 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "NeurogesX Announces Resignation of EVP of Research and Development and Chief Medical Officer Jeffrey K Tobias, MD Dr. Tobias to Consult on Near Term Clinical and Regulatory Activities"
09/26/2011 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "2011 Inducement Stock Plan"
09/08/2011 8-K Other Events, Financial Statements and Exhibits
Docs: "The Ruth Group"
08/09/2011 8-K Form 8-K - Current report
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy